## Deborah R Kaye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4248097/publications.pdf

Version: 2024-02-01

21 249 8 papers citations h-index

21 21 21 468 all docs docs citations times ranked citing authors

16

g-index

#	Article	IF	CITATIONS
1	Understanding the Costs Associated With Surgical Care Delivery in the Medicare Population. Annals of Surgery, 2020, 271, 23-28.	2.1	61
2	Costs of Cancer Care Across the Disease Continuum. Oncologist, 2018, 23, 798-805.	1.9	37
3	The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. Urology, 2020, 145, 106-112.	0.5	23
4	Understanding the relationship between the Centers for Medicare and Medicaid Services' Hospital Compare star rating, surgical case volume, and shortâ€term outcomes after major cancer surgery. Cancer, 2017, 123, 4259-4267.	2.0	21
5	Association Between Patient Satisfaction and Short-Term Outcomes After Major Cancer Surgery. Annals of Surgical Oncology, 2017, 24, 3486-3493.	0.7	21
6	Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU International, 2019, 123, 846-853.	1.3	21
7	Episode-based Payment Variation for Urologic Cancer Surgery. Urology, 2018, 111, 78-85.	0.5	14
8	Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer. Urology, 2018, 118, 127-133.	0.5	10
9	Alternative payment models and urology. Current Opinion in Urology, 2017, 27, 360-365.	0.9	8
10	Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States. Kidney Cancer, 2021, 5, 115-127.	0.2	8
11	Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance. Urology, 2021, 147, 213-222.	0.5	7
12	Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Practice, 2021, 17, OP.20.01082.	1.4	6
13	Use of Routine Home Health Care and Deviations From an Uncomplicated Recovery Pathway After Radical Prostatectomy. Urology, 2018, 112, 74-79.	0.5	5
14	The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program. Urology, 2019, 123, 114-119.	0.5	3
15	Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. Journal of Geriatric Oncology, 2022, 13, 614-623.	0.5	2
16	The Impact of Health Delivery Integration on Cancer Outcomes. Surgical Oncology Clinics of North America, 2022, 31, 91-108.	0.6	1
17	Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. Journal of Geriatric Oncology, 2022, 13, 635-643.	0.5	1
18	Variation in Physician-Specific Episode Payments for Major Cancer Surgery and Implications for the Merit-Based Incentive Program. Journal of Surgical Research, 2019, 236, 30-36.	0.8	0

#	Article	IF	CITATIONS
19	Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation in Aging, 2021, 5, 703-703.	0.0	0
20	Improving health equity for older people with serious illness through value based payment reform. Journal of the American Geriatrics Society, 2022, 70, 2180-2185.	1.3	0
21	Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal of the American Geriatrics Society, 2022, 70, 2330-2343.	1.3	O